|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
46,110,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile BioAtla is a biopharmaceutical company engaged in developing specific and selective antibody-based therapeutics for the treatment of various cancers. Co.'s lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. Co. also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
81,495 |
83,495 |
252,735 |
Total Buy Value |
$0 |
$172,540 |
$177,620 |
$814,041 |
Total People Bought |
0 |
4 |
4 |
4 |
Total Buy Transactions |
0 |
4 |
5 |
15 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Short Jay M Phd |
Chief Executive Officer |
|
2022-06-30 |
4 |
D |
$2.85 |
$8,231 |
D/D |
(2,888) |
1,373,094 |
|
- |
|
Waldron Richard A |
Chief Financial Officer |
|
2022-06-30 |
4 |
D |
$2.85 |
$2,765 |
D/D |
(970) |
127,594 |
|
- |
|
Vasquez Christian |
See Remarks |
|
2022-06-30 |
4 |
D |
$2.85 |
$553 |
D/D |
(194) |
74,331 |
|
- |
|
Smith Scott Andrew |
President |
|
2022-06-30 |
4 |
D |
$2.85 |
$5,104 |
D/D |
(1,791) |
331,626 |
|
- |
|
Sievers Eric |
Chief Medical Officer |
|
2022-06-30 |
4 |
D |
$2.85 |
$1,582 |
D/D |
(555) |
87,281 |
|
- |
|
Short Jay M Phd |
Chief Executive Officer |
|
2022-06-22 |
4 |
AB |
$2.91 |
$117,296 |
D/D |
40,308 |
1,375,982 |
|
- |
|
Short Jay M Phd |
Chief Executive Officer |
|
2022-06-21 |
4 |
AB |
$2.79 |
$81,040 |
D/D |
29,082 |
1,335,674 |
|
- |
|
Smith Scott Andrew |
President |
|
2022-05-31 |
4 |
D |
$2.41 |
$4,316 |
D/D |
(1,791) |
333,417 |
|
- |
|
Short Jay M Phd |
Chief Executive Officer |
|
2022-05-31 |
4 |
D |
$2.41 |
$6,960 |
D/D |
(2,888) |
1,306,592 |
|
- |
|
Vasquez Christian |
See Remarks |
|
2022-05-31 |
4 |
D |
$2.41 |
$468 |
D/D |
(194) |
24,525 |
|
- |
|
Waldron Richard A |
Chief Financial Officer |
|
2022-05-31 |
4 |
D |
$2.41 |
$2,338 |
D/D |
(970) |
128,564 |
|
- |
|
Sievers Eric |
Chief Medical Officer |
|
2022-05-31 |
4 |
D |
$2.41 |
$1,335 |
D/D |
(554) |
87,836 |
|
- |
|
Smith Scott Andrew |
President |
|
2022-03-31 |
4 |
D |
$5.00 |
$8,955 |
D/D |
(1,791) |
336,999 |
|
- |
|
Vasquez Christian |
See Remarks |
|
2022-03-31 |
4 |
D |
$5.00 |
$945 |
D/D |
(189) |
24,908 |
|
- |
|
Waldron Richard A |
Chief Financial Officer |
|
2022-03-31 |
4 |
D |
$5.00 |
$4,850 |
D/D |
(970) |
130,504 |
|
- |
|
Short Jay M Phd |
Chief Executive Officer |
|
2022-03-31 |
4 |
D |
$5.00 |
$14,440 |
D/D |
(2,888) |
1,306,990 |
|
- |
|
Sievers Eric |
Chief Medical Officer |
|
2022-03-31 |
4 |
D |
$5.00 |
$2,770 |
D/D |
(554) |
88,945 |
|
- |
|
Sievers Eric |
Chief Medical Officer |
|
2022-02-28 |
4 |
D |
$6.48 |
$3,596 |
D/D |
(555) |
89,499 |
|
- |
|
Smith Scott Andrew |
President |
|
2022-02-28 |
4 |
D |
$6.48 |
$11,606 |
D/D |
(1,791) |
338,790 |
|
- |
|
Waldron Richard A |
Chief Financial Officer |
|
2022-02-28 |
4 |
D |
$6.48 |
$6,286 |
D/D |
(970) |
131,474 |
|
- |
|
Vasquez Christian |
See Remarks |
|
2022-02-28 |
4 |
D |
$6.48 |
$1,490 |
D/D |
(230) |
25,097 |
|
- |
|
Short Jay M Phd |
Chief Executive Officer |
|
2022-02-28 |
4 |
D |
$6.48 |
$18,714 |
D/D |
(2,888) |
1,309,878 |
|
- |
|
Waldron Richard A |
Chief Financial Officer |
|
2022-01-31 |
4 |
D |
$9.56 |
$10,994 |
D/D |
(1,150) |
132,444 |
|
- |
|
Smith Scott Andrew |
President |
|
2022-01-31 |
4 |
D |
$9.56 |
$20,850 |
D/D |
(2,181) |
340,581 |
|
- |
|
Vasquez Christian |
See Remarks |
|
2022-01-31 |
4 |
D |
$9.56 |
$2,199 |
D/D |
(230) |
25,327 |
|
- |
|
135 Records found
|
|
Page 3 of 6 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|